GAM
REGN icon

Groupama Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Groupama Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.1M Buy
77,940
+6,838
+10% +$4.65M 0.62% 42
2026
Q1 		$54.9M Sell
71,102
-80
-0.1% -$61.2K 0.8% 37
2025
Q4 		$54.9M Buy
71,182
+8,481
+14% +$5.76M 0.8% 34
2025
Q3 		$35.3M Sell
62,701
-5,169
-8% -$2.92M 0.52% 46
2025
Q2 		$35.4M Sell
67,870
-22,742
-25% -$12.7M 0.59% 41
2025
Q1 		$57.8M Buy
90,612
+10,273
+13% +$7.07M 1.15% 24
2024
Q4 		$56.4M Buy
80,339
+9,062
+13% +$7.61M 1.15% 24
2024
Q3 		$60.2M Buy
71,277
+4,648
+7% +$5.17M 1.56% 17
2024
Q2 		$70M Buy
66,629
+16,417
+33% +$15.9M 0.95% 24
2024
Q1 		$64.5M Sell
50,212
-17,159
-25% -$16.3M 1.18% 21
2023
Q4 		$59.2M Buy
+67,371
New +$55.5M 1.54% 14

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Groupama Asset Management's REGN Position: Q2 2026 in Review

Groupama Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 9.6% in Q2 2026, buying an estimated $4.65M and bringing the position to 77,940 shares worth $49.1M. The position accounts for 0.62% of the portfolio, ranked #42.

Groupama Asset Management first reported a position in REGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $70M in Q2 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Groupama Asset Management held 77,940 shares of Regeneron Pharmaceuticals worth $49.1M as of Q2 2026.
  • Groupama Asset Management bought 6,838 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.65M.
  • Regeneron Pharmaceuticals made up 0.62% of Groupama Asset Management's portfolio in Q2 2026, its #42 holding.
  • Groupama Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Groupama Asset Management's Regeneron Pharmaceuticals position peaked at $70M in Q2 2024.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Groupama Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.